Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safest and most effective oral dose
combinations of sorafenib and irinotecan in pediatric patients with solid tumors, i.e.
relapsed or refractory.